In mouse experiments, blocking FcγR prior to anti–PD-1 drug administration can significantly prolong the binding of the monoclonal antibody to CD8+ tumor-infiltrating T cells and improved the antitumor effect of immunotherapy (99). Here, PDCD1 is linked to neoplasm.